12 Health Care Stocks Moving In Monday's Intraday Session

Benzinga · 03/16 17:05
Gainers
- HCW Biologics (NASDAQ:HCWB) stock increased by 116.0% to $1.11 during Monday's regular session. The market value of their outstanding shares is at $2.9 million.
- CytomX Therapeutics (NASDAQ:CTMX) stock rose 71.36% to $8.02. The market value of their outstanding shares is at $792.9 million. As per the press release, Q4 earnings came out today.
- AirSculpt Technologies (NASDAQ:AIRS) shares moved upwards by 57.3% to $2.91. The company's market cap stands at $115.5 million.
- Acurx Pharmaceuticals (NASDAQ:ACXP) stock increased by 38.14% to $5.36. The company's market cap stands at $9.8 million. As per the press release, Q4 earnings came out yesterday.
- NovaBay Pharmaceuticals (AMEX:NBY) shares rose 24.03% to $1.5. The company's market cap stands at $31.6 million.
- Artelo Biosciences (NASDAQ:ARTL) stock moved upwards by 23.4% to $4.64. The company's market cap stands at $7.5 million.
Losers
- Nasus Pharma (AMEX:NSRX) stock declined by 44.2% to $2.79 during Monday's regular session. The company's market cap stands at $58.5 million.
- Lifecore Biomedical (NASDAQ:LFCR) stock declined by 29.21% to $4.63. The market value of their outstanding shares is at $245.0 million. As per the press release, Q2 earnings came out today.
- bioAffinity Technologies (NASDAQ:BIAF) stock declined by 24.3% to $1.6. The company's market cap stands at $9.5 million.
- Firefly Neuroscience (NASDAQ:AIFF) stock decreased by 18.19% to $2.25. The company's market cap stands at $39.0 million.
- Axe Compute (NASDAQ:AGPU) shares fell 17.95% to $1.6. The company's market cap stands at $6.6 million.
- Polaryx Therapeutics (NASDAQ:PLYX) stock decreased by 16.04% to $5.34. The company's market cap stands at $301.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.